Abstract
The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective legality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.
Original language | English (US) |
---|---|
U.S. patent number | 10576096 |
Filing date | 12/6/17 |
State | Published - Mar 3 2020 |